Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity

Clinical Cancer Research

Volumn 22, Issue 20, 2016, Pages 5130-5140

  Ballard, Peter ^a   Yates, James W T ^a   Yang, Zhenfan ^a   Kim, Dong Wan ^b   Yang, James Chih Hsin ^c   Cantarini, Mireille ^a   Pickup, Kathryn ^a   Jordan, Angela ^a   Hickey, Mike ^a   Grist, Matthew ^a   Box, Matthew ^a   Johnström, Peter ^d,e   Varnäs, Katarina ^e   Malmquist, Jonas ^e   Thress, Kenneth S ^a   Jänne, Pasi A ^f   Cross, Darren ^a  

^a ASTRAZENECA   (United Kingdom)

^b Seoul National University Hospital   (South Korea)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d ASTRAZENECA R AND D   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBON 11; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; OSIMERTINIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ROCILETINIB; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CACO 2 CELL LINE; CANCER RADIOTHERAPY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MDCK CELL LINE; MEDICAL DECISION MAKING; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CACO-2 CELL LINE; COMPARATIVE STUDY; DISEASE EXACERBATION; DOG; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MOUSE; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; RAT; SCID MOUSE; SECONDARY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CACO-2 CELLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, SCID; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991730676     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0399     Document Type: Article

References (47)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology NSCLC (version 7.2015), 2015 [cited 2015 Jul 16]. Available from: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf.
2. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic therapy for Stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015;33:3488-515.
3. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007;242:882-8.
4. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010;16: 5873-82.
5. Garg P, Dhakne R, Belekar V. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability. Mol Divers 2015;19:163-72.
6. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012; 70:399-405.
7. Bartolotti M, Franceschi E, Brandes AA. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev Anticancer Ther 2012;12:1429-35.
8. Ding YL, Shih YH, Tsai FY, Leong MK. In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2). PLoS One 2014;9:e90689.
9. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATPbinding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011;17:89-99.
10. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 2011;3:153-60.
11. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72.
12. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2012;18:4406-14.
13. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated nonsmall-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2015;10:156-63.
14. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;82:282-7.
15. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556-60.
16. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-9.
17. Committee for Medicinal Products for Human Use. Committee for Medicinal Products for Human Use (CHMP) assessment report for Giotrif (afatinib). European Medicines Agency 2013.
18. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012;30:443-9.
19. European Medicines Agency. Iressa summary of product characteristics, 2009[cited 2015 Oct 22].
20. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005;103:2344-8.
21. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 3:53-7.
22. Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 2014;40:716-22.
23. Rangachari D, Yamaguchi N, Van der Laan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88:108-11.
24. Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008;71:64-70.
25. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4:1046-61.
26. Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249-67.
27. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-9.
28. U.S. Food and Drug Administration. FDA approves new pill to treat certain patients with non-small cell lung cancer, 2015 [cited 2015 Nov 13]. Available from:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
29. Varrone A, Sjöholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009;36: 1639-50.
30. Hochgrafe K, Mandelkow EM. Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration. Mol Neurobiol 2013;47: 868-82.
31. Kemper EM, Leenders W, Kusters B, Lyons S, Buckle T, Heerschap A, et al. Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies. Eur J Cancer 2006;42:3294-303.
32. Schackert G, Fan D, Nayar R, Fidler IJ. Arrest and retention of multilamellar liposomes in the brain of normalmice or mice bearing experimental brain metastases. Sel Cancer Ther 1989;5:73-9.
33. Schackert G, Fidler IJ. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res 1988;48:3478-84.
34. Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P. Irreversible inhibition of EGFR: Modelling the combined Pharmacokinetic-Pharmacodynamic relationship of osimertinib and its active metabolite AZ5104. Mol Cancer Ther 2016; Jul 20. pii: molcanther.0142.2016. [Epub ahead of print]
35. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
36. Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol 2005; 18:654-61.
37. McTyre E, Scott J, Chinnaiyan P. Whole brain radiotherapy for brain metastasis. Surg Neurol Int 2013;4:S236-44.
38. Varadharajan S, Winiwarter S, Carlsson L, Engkvist O, Anantha A, Kogej T, et al. Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation. J Pharm Sci 2015;104:1197-206.
39. McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CM, Clarkson-Jones JA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004;34:917-34.
40. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009;69:873-8.
41. Planchard D, Dickinson PA, Brown KH, Kim D, Kim S, Ohe Y, et al. Preliminary AZD9291 Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose and dosing frequency in pivotal clinical studies. Ann Oncol 2014;25(Suppl 4): Abstract 464P.
42. Kim D, Yang JC, Chen K, Cheng Z, Yin L, Martin PD, et al. AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): preclinical evidence and clinical cases. J Clin Oncol 33, 2015 (suppl; abstr 8016).
43. Schou M, Varnäs K, Lundquist S, Nakao R, Amini N, Takano A, et al. Large variation in brain exposure of reference CNS drugs: a PET study in nonhuman primates. Int J Neuropsychopharmacol 2015;18:pii: pyv036.
44. Johnström P, Varnäs K, Bergman L, Malmquist J, Halldin C, Farde L. Estimation of the unbound brain to plasma ratio for CNS drug candidates-comparing results obtained with PET microdosing and microdialysis in non-human primates. J Labelled Compd Radiopharm 2015;58:S314.
45. Johnström P, Bergman L, Varnäs K, Malmquist J, Halldin C, Farde L. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol 2015;42:555-60.
46. Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varnäs K, Johnström P, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain 2015;138:2687-700.
47. Herrlinger U, Forschler H, Kuker W, Meyermann R, Bamberg M, Dichgans J, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004;223:167-78.